[
    [
        {
            "time": "",
            "original_text": "药企名单 | 通过2019年复核评价的国家技术创新示范企业名单；天士力、扬子江、齐鲁、恒瑞等",
            "features": {
                "keywords": [
                    "药企",
                    "国家技术创新",
                    "天士力",
                    "扬子江",
                    "齐鲁",
                    "恒瑞"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药企名单 | 通过2019年复核评价的国家技术创新示范企业名单；天士力、扬子江、齐鲁、恒瑞等",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "数图说丨恒瑞市值逼近3000亿！领跑医药股凭的啥本事？",
            "features": {
                "keywords": [
                    "恒瑞",
                    "市值",
                    "医药股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "数图说丨恒瑞市值逼近3000亿！领跑医药股凭的啥本事？",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "北上资金跑步进场！本周净买入200亿，前三甲公司吸金45亿！注意，这个题材遭清仓式减持 减持股份",
            "features": {
                "keywords": [
                    "北上资金",
                    "净买入",
                    "减持"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "北上资金跑步进场！本周净买入200亿，前三甲公司吸金45亿！注意，这个题材遭清仓式减持 减持股份",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "陆股通连续净买入股名单",
            "features": {
                "keywords": [
                    "陆股通",
                    "净买入"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "陆股通连续净买入股名单",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "仿制药目录建议清单出炉，受益股有哪些？",
            "features": {
                "keywords": [
                    "仿制药",
                    "目录",
                    "受益股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "仿制药目录建议清单出炉，受益股有哪些？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药白马信立泰之痛：产品青黄不接 研发投入处理激进",
            "features": {
                "keywords": [
                    "医药",
                    "信立泰",
                    "研发投入",
                    "青黄不接"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药白马信立泰之痛：产品青黄不接 研发投入处理激进",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "东海证券发布医药行业中期策略：两维度布局",
            "features": {
                "keywords": [
                    "东海证券",
                    "医药行业",
                    "中期策略",
                    "两维度布局"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "东海证券发布医药行业中期策略：两维度布局",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "头顶千亿港元市值，翰森制药能否“撇清”恒瑞医药？“夫妻店”巨额销售费用双双待查",
            "features": {
                "keywords": [
                    "翰森制药",
                    "恒瑞医药",
                    "市值",
                    "销售费用",
                    "调查"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "头顶千亿港元市值，翰森制药能否“撇清”恒瑞医药？“夫妻店”巨额销售费用双双待查",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]